Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

A Web-Based Survey on Suggested Modifications in the Management of Patients with Breast Cancer During the COVID-19 Pandemic

2021 Year in Review - Breast Cancer - Breast Cancer

In the current era of the COVID-19 pandemic, the management of patients with cancer is a huge problem for healthcare systems. However, maintaining the required level of cancer care while taking the essential steps to ensure the safety of patients and healthcare professionals is necessary. To maintain the balance between patient care and safety, some changes in the medical management of patients with cancer, such as surgical approaches, locoregional and systemic therapies, as well as adjustments in treatment and follow-up regimens are required. Furthermore, determining medical care priorities may be necessary when available health services fall short of the number of patients. Patients with cancer are a diverse group with a variety of symptoms, stages at diagnosis, tumor load, and therapy options, all of which come with their own set of side effects and immune suppression. This could put patients with cancer at risk for COVID-19–related problems.1

COVID-19 infection puts patients with cancer at a higher risk for developing severe illness and death. Case fatality rates recorded among patients hospitalized with COVID-19 are higher than those reported among other patients, with 29.4% versus 10.2%, respectively.1 Even after accounting for age, sex, diabetes, smoking, cardiovascular and pulmonary illness, and other major risk factors for COVID-19 severity, large cohort studies consistently show that patients with cancer have a greater risk for all-cause mortality and intensive care unit admission. These findings emphasize the urgent need to reduce the risk for COVID-19 infection in patients with cancer.2

COVID-19 infection is more common in patients with breast cancer for a variety of causes, including myelosuppression caused by chemotherapy used in neoadjuvant, adjuvant, or metastatic situations; cyclin-dependent kinase 4/6 inhibitors; and palliative radiotherapy to the spine or pelvis.1

Myelosuppression may also be caused by metastatic tumor cells infiltrating the bone marrow. The European Society for Medical Oncology, the American College of Surgeons, and the National Comprehensive Cancer Network all issued suggestions and recommendations addressing possible treatment modifications and precautions in the management of patients with cancer in the era of the COVID-19 pandemic. The fundamental focus of the expert-based advice is to reduce the likelihood and/or length of neutropenia, reduce the frequency of hospital visits and stays, and to avoid drugs that may be dangerous during the current COVID-19 epidemic. The European Society for Medical Oncology recommendations, for example, divide the management of patients with breast cancer into low, medium, and high medical care priorities. Similarly, Cancer Care Ontario, Canada, observed differing priorities for medical care of patients with cancer who were treated with a variety of therapeutic modalities such as surgery, radiation, systemic therapy, and palliative care.1

As a result, during the COVID-19 pandemic, the risk–benefit ratio of various treatment options may need to be reviewed to choose the appropriate therapeutic strategy for each patient. Therefore, multidisciplinary tumor board discussions and assessments of available hospital facilities are vital. Furthermore, it is critical to assess how practicing oncologists respond to these therapeutic modification recommendations and whether they are implemented in real life. Results of a recent web-based survey show what doctors treating patients with breast cancer think about probable changes in breast cancer management during the current COVID-19 epidemic.1

References

  1. Elsamany S, Elbaiomy M, Zeeneldin A, et al. Suggested modifications to the management of patients with breast cancer during the COVID-19 pandemic: web-based survey study. JMIR Cancer. 2021;7:e27073.
  2. Garrigós L, Saura C, Martinez-Vila C, et al. COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. Ther Adv Med Oncol. 2021;13:17588359211053416.
Related Items
Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Breast Cancer
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Breast Cancer
Pembrolizumab plus Chemotherapy for Neoadjuvant and Adjuvant Therapy in Early Triple-Negative Breast Cancer: KEYNOTE-522
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in From the Literature, Breast Cancer, Checkpoint Inhibitors
Evaluating Adverse Events in Patients with Breast Cancer and HIV Infection Receiving Concomitant Antiretroviral Therapy and Chemotherapy with Curative Intent
Donyika Joseph, PharmD, BCOP, Farnaz Foolad, PharmD, BCPS, Neelam K. Patel, PharmD, BCOP, Meghan Karuturi, MD, MSc, Jaime Kaushik, PharmD, BCOP
JHOP - April 2022 Vol 12, No 2 published on May 2, 2022 in Original Article, Adverse Events, Breast Cancer, Infections
Advances in Breast Cancer Treatments: Are We Extending Patients’ Survival?
Meg Barbor, MPH
JHOP - June 2019 Vol 9, No 2 published on April 28, 2022 in HOPA Highlights, Breast Cancer
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Time to Treatment Initiation and Outcomes for Patients with Nonmetastatic Breast Cancer Before and During the COVID-19 Pandemic at Community Cancer Centers
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Spontaneous Tumor Lysis Syndrome in a Patient with Stage IV HER2-Positive Breast Cancer: Case Report
Blake T. Robbins, PharmD, MBA , Alexander M. Kreimer, PharmD, BCPS , Reema A. Patel, MD, Allison R. Butts, PharmD, BCOP
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Case Reports, Tumor Lysis Syndrome, Breast Cancer
Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic Triple-Negative Breast Cancer: Applying the Lessons from Clinical Trials to Clinical Practice
February 2022 Clinical Trials to Clinical Practice published on February 3, 2022 in Clinical Trials, Breast Cancer
2021 Breast Cancer Year in Review Introduction
2021 Year in Review - Breast Cancer published on January 21, 2022 in Breast Cancer
Copyright © The Lynx Group, LLC. All rights reserved.